(89)Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection

The hepatocyte growth factor (HGF) binding antibody rilotumumab (AMG102) was modified for use as a (89)Zr-based immuno-PET imaging agent to noninvasively determine the local levels of HGF protein in tumors. Because recent clinical trials of HGF-targeting therapies have been largely unsuccessful in s...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Nucl Med
Asıl Yazarlar: Price, Eric W., Carnazza, Kathryn E., Carlin, Sean D., Cho, Andrew, Edwards, Kimberly J., Sevak, Kuntal K., Glaser, Jonathan M., de Stanchina, Elisa, Janjigian, Yelena Y., Lewis, Jason S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Society of Nuclear Medicine 2017
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5577625/
https://ncbi.nlm.nih.gov/pubmed/28280216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.116.187310
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller